0

ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another γ-secretase Inhibitor Fails in the Clinic

Corey R Hopkins

ACS Chem Neurosci. 2011 Jun 15;2(6):279-80.

PMID: 22778871

Abstract:

ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1333990843 ELND006 ELND006 1333990-84-3 Price
qrcode